Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

opicapone

- PMLiVE

Prothena achieves $60m milestone as part of Roche collaboration

Milestone reached as first patient doses in phase 2b trial of prasinezumab in early Parkinson's disease patients

- PMLiVE

EU asks AZ to deliver 120 million COVID-19 vaccines by the end of June

The EU has launched a new lawsuit against the drugmaker which could result in financial sanctions

- PMLiVE

EU moves forward with legal action against AZ over vaccine supply issues

Legal proceeding launched on the basis of 'breaches of the advanced purchase agreement'

- PMLiVE

EU may seek legal action against AstraZeneca following vaccine supply cuts

EU supply issues for the AZ vaccine started in January 2021

Roche Basel Switzerland

Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues

Company continues to report a significant impact of biosimilar competition on established brands

Roche Basel Switzerland

Roche’s Ocrevus shows significant benefit in early-stage MS patients

The data was presented virtually at the American Academy of Neurology annual meeting

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

- PMLiVE

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma

- PMLiVE

FDA approves new self-injection administration for Xolair

Drug is approved for asthma and other allergic and inflammatory conditions

- PMLiVE

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

MHRA is looking "very closely" at reports of adverse reactions to coronavirus vaccines

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk

REGEN-COV reduced the risk of symptomatic infections by 81% in a phase 3 prevention trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links